gutflix
GI learning, personalised

Summary

LONG-TERM FOLLOW UP OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED FOR CYTOMEGALOVIRUS COLITIS

Jonathan Segal

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

A retrospective study of 14 IBD patients with CMV colitis found high rates of CMV recurrence, hospitalisation, and colectomy over 12 months, with only 29% achieving disease remission.

KEY POINTS

- Among 14 IBD patients treated for CMV colitis at Royal Melbourne Hospital between 2018-2023, CMV colitis recurred in 21% at 6 months and 29% at 12 months.
- At 12 months, 36% of patients had been re-hospitalised due to IBD or CMV, and 3 colectomies had occurred.
- Forty-three percent of patients changed their biologic therapy and 29% escalated their biologic dose by 6 months, with rates remaining constant at 12 months.
- Disease remission was achieved by only 7% of patients at 6 months and 29% at 12 months.
- The authors conclude that CMV colitis may be a negative prognostic marker in IBD, with risks potentially greater within 6 months of the index episode.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/191ae660-9112-11ef-8365-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.